Edition:
United States

Cumberland Pharmaceuticals Inc (CPIX.OQ)

CPIX.OQ on NASDAQ Stock Exchange Global Select Market

7.01USD
12:49pm EDT
Change (% chg)

$-0.02 (-0.28%)
Prev Close
$7.03
Open
$7.05
Day's High
$7.05
Day's Low
$7.01
Volume
504
Avg. Vol
8,685
52-wk High
$7.32
52-wk Low
$4.41

CPIX.OQ

Chart for CPIX.OQ

About

Cumberland Pharmaceuticals Inc. (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company's product portfolio includes Acetadote (acetylcyste... (more)

Overall

Beta: 0.98
Market Cap(Mil.): $112.72
Shares Outstanding(Mil.): 16.03
Dividend: --
Yield (%): --

Financials

  CPIX.OQ Industry Sector
P/E (TTM): -- 14.35 17.42
EPS (TTM): -0.12 -- --
ROI: -2.60 -7.29 -5.45
ROE: -2.66 -6.80 -4.73

BRIEF-Stonepine Capital Management reports 6.8 percent passive stake in Cumberland Pharmaceuticals

* Stonepine Capital Management Llc reports 6.8 percent passive stake in Cumberland Pharmaceuticals Inc as of May 9 - SEC filing Source text for Eikon: (http://bit.ly/2qA4bqN) Further company coverage:

May 19 2017

BRIEF-Cumberland Pharmaceuticals reports q1 adjusted EPS $0.02

* Cumberland pharmaceuticals reports revenue growth of 25% in first quarter 2017

May 15 2017

BRIEF-Cumberland Pharmaceuticals entered into a co-promotion partnership with Poly Pharmaceuticals for Kristalose within U.S.

* Cumberland Pharmaceuticals Inc - Entered into a co-promotion partnership with Poly Pharmaceuticals Inc for Kristalose within United States

Apr 26 2017

BRIEF-Cumberland Pharmaceuticals says caldolor demonstrates significant post surgical pain reduction and decrease in opioid use

* Cumberland Pharmaceuticals Inc says Caldolor demonstrates significant post surgical pain reduction and decrease in opioid use Source text for Eikon: Further company coverage:

Mar 27 2017

Cumberland defeats Mylan’s appeal on Acetadote patent

A federal appeals court on Thursday dealt another blow to Mylan Inc’s plans to offer a generic version of an improved antidote for acetaminophen poisoning, ruling that Cumberland Pharmaceutical’s patent on the product was valid.

Jan 27 2017

BRIEF-Cumberland Pharmaceuticals, Clinigen enter U.S. commercialization agreement for Totect

* Cumberland pharmaceuticals and Clinigen enter exclusive U.S. commercialization agreement for Totect

Jan 09 2017

More From Around the Web

Earnings vs. Estimates